 Immunization, Passive
"Immunization, Passive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER).
| Descriptor ID |
D007116
|
| MeSH Number(s) |
E02.095.465.425.400.330 E05.478.550.520
|
| Concept/Terms |
Immunization, Passive- Immunization, Passive
- Immunizations, Passive
- Passive Immunization
- Passive Immunizations
Passive Antibody Transfer- Passive Antibody Transfer
- Antibody Transfer, Passive
- Antibody Transfers, Passive
- Passive Antibody Transfers
- Transfer, Passive Antibody
- Transfers, Passive Antibody
- Passive Transfer of Immunity
Immunotherapy, Passive- Immunotherapy, Passive
- Passive Immunotherapy
- Immunotherapies, Passive
- Passive Immunotherapies
Immunoglobulin Therapy- Immunoglobulin Therapy
- Therapy, Immunoglobulin
- Immunoglobulin Therapies
- Therapies, Immunoglobulin
|
Below are MeSH descriptors whose meaning is more general than "Immunization, Passive".
Below are MeSH descriptors whose meaning is more specific than "Immunization, Passive".
This graph shows the total number of publications written about "Immunization, Passive" by people in this website by year, and whether "Immunization, Passive" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 2001 | 0 | 2 | 2 | | 2002 | 1 | 2 | 3 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 1 | 2 | | 2011 | 0 | 1 | 1 | | 2014 | 2 | 1 | 3 | | 2015 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 6 | 6 | | 2021 | 0 | 12 | 12 | | 2022 | 0 | 4 | 4 | | 2023 | 0 | 2 | 2 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunization, Passive" by people in Profiles.
-
Knowlton KU, Siegel LK, Barkauskas CE, Bhagani S, Dharan NJ, Gardner EM, Gottlieb RL, Helleberg M, Highbarger HC, Holland TL, Heerfordt CK, Lazarte S, Leither LM, Lutaakome J, Ardelt M, Mylonakis E, Ong SWX, Overcash JS, Taha H, Tien PC, Trautner BW, Vallee D, Weintrob AC, Touloumi G, Babiker AG. Passive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials. PLoS Med. 2025 Jul; 22(7):e1004616.
-
Janoff EN, Shih MC, Donskey C, Belitskaya-Levy I, Brau N, Rodriguez-Barradas MC, Chan E, Zimmerman P, Miller EK, Vaughan LB, Daniel Markley J, Goldberg AM, Sriram P, Anzueto A, Uyeda L, Zehm L, Wills A, Hutchinson C, Jones L, Peterson D, Ringer RJ, Dumont L, Gleason T, Bonomo RA, Curtis JL, Brown ST. Impact of High-Titer Convalescent Plasma on Clinical and Virologic Outcomes Among Veterans Hospitalized With SARS-CoV-2 Infection: VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1). J Med Virol. 2025 May; 97(5):e70349.
-
Mourad A, Grandits GA, Siegel LK, Engen N, Barkauskas C, Eriobu N, Jain MK, Jensen TO, Ginde A, Higgs E, Knox DB, Kitonsa J, Kim K, Malin JJ, Rapti V, Price DA, Mena Lora AJ, Mathews G, Mylonakis E, Murray TA, Sandkovsky U, Paredes R, Ramachandruni S, Reilly C, Vock D, Williamson JC, Young BE, Self WH, Lundgren J, Holland TL. Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial. Clin Microbiol Infect. 2025 Jun; 31(6):1053-1060.
-
Jacquot C, Gordon O, Noland D, Donowitz JR, Levy E, Jain S, Willis Z, Rimland C, Loi M, Arrieta A, Annen K, Drapeau N, Osborne S, Ardura MI, Arora S, Zivick E, Delaney M. Multi-institutional experience with COVID-19 convalescent plasma in children. Transfusion. 2023 05; 63(5):918-924.
-
Shoham S, Bloch EM, Casadevall A, Hanley D, Lau B, Gebo K, Cachay E, Kassaye SG, Paxton JH, Gerber J, Levine AC, Naeim A, Currier J, Patel B, Allen ES, Anjan S, Appel L, Baksh S, Blair PW, Bowen A, Broderick P, Caputo CA, Cluzet V, Cordisco ME, Cruser D, Ehrhardt S, Forthal D, Fukuta Y, Gawad AL, Gniadek T, Hammel J, Huaman MA, Jabs DA, Jedlicka A, Karlen N, Klein S, Laeyendecker O, Lane K, McBee N, Meisenberg B, Merlo C, Mosnaim G, Park HS, Pekosz A, Petrini J, Rausch W, Shade DM, Shapiro JR, Singleton JR, Sutcliffe C, Thomas DL, Yarava A, Zand M, Zenilman JM, Tobian AAR, Sullivan DJ. Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. Clin Infect Dis. 2023 02 08; 76(3):e477-e486.
-
Chauhan L, Pattee J, Ford J, Thomas C, Lesteberg K, Richards E, Bernas CA, Loi M, Dumont L, Annen K, Berg M, Zirbes M, Knight V, Miller A, Jenkins TC, Bennett TD, Monkowski D, Boxer RS, Beckham JD. A Multicenter, Prospective, Observational, Cohort-Controlled Study of Clinical Outcomes Following Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Therapy in Hospitalized Patients With COVID-19. Clin Infect Dis. 2022 08 24; 75(1):e466-e472.
-
Van Rompay KKA, Olstad KJ, Sammak RL, Dutra J, Watanabe JK, Usachenko JL, Immareddy R, Roh JW, Verma A, Shaan Lakshmanappa Y, Schmidt BA, Di Germanio C, Rizvi N, Liu H, Ma ZM, Stone M, Simmons G, Dumont LJ, Allen AM, Lockwood S, Pollard RE, Ramiro de Assis R, Yee JL, Nham PB, Ardeshir A, Deere JD, Jain A, Felgner PL, Coffey LL, Iyer SS, Hartigan-O'Connor DJ, Busch MP, Reader JR. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation. PLoS Pathog. 2022 04; 18(4):e1009925.
-
Tasli NP, Gönen ZB, Kirbas OK, Gökdemir NS, Bozkurt BT, Bayrakci B, Sagraç D, Taskan E, Demir S, Ekimci Gürcan N, Bayindir Bilgiç M, Bayrak ÖF, Yetiskin H, Kaplan B, Pavel STI, Dinç G, Serhatli M, Çakirca G, Eken A, Aslan V, Yay M, Karakukcu M, Unal E, Gül F, Basaran KE, Ozkul Y, Sahin F, Jones OY, Tekin S, Özdarendeli A, Cetin M. Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2. Front Immunol. 2022; 13:824378.
-
Miller EK, Goldberg AM, Janoff EN, Brown ST, Curtis JL, Bonomo RA, Shih MC, Gleason TC. Designing and implementing methodology for double-blind, placebo-controlled clinical trials using blood products within the Department of Veterans Affairs. Clin Trials. 2022 04; 19(2):137-145.
-
Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA, Klassen SA, Klompas AM, Sexton MA, Diaz Soto JC, Grossman BJ, Tobian AAR, Goel R, Wiggins CC, Bruno KA, van Buskirk CM, Stubbs JR, Winters JL, Casadevall A, Paneth NS, Shaz BH, Petersen MM, Sachais BS, Buras MR, Wieczorek MA, Russoniello B, Dumont LJ, Baker SE, Vassallo RR, Shepherd JRA, Young PP, Verdun NC, Marks P, Haley NR, Rea RF, Katz L, Herasevich V, Waxman DA, Whelan ER, Bergman A, Clayburn AJ, Grabowski MK, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Buchholtz ZA, Pletsch MC, Wright K, Greenshields JT, Joyner MJ, Wright RS, Carter RE, Fairweather D. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med. 2021 12; 18(12):e1003872.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|